NO20075224L - Prosess og fremgangsmater for fremstilling av optisk aktiv CIS-2-hydroxymethyl-4-(cytosin-1'-YL)-1,3 oxathiolan eller farmasoytisk akseptable salter derav - Google Patents

Prosess og fremgangsmater for fremstilling av optisk aktiv CIS-2-hydroxymethyl-4-(cytosin-1'-YL)-1,3 oxathiolan eller farmasoytisk akseptable salter derav

Info

Publication number
NO20075224L
NO20075224L NO20075224A NO20075224A NO20075224L NO 20075224 L NO20075224 L NO 20075224L NO 20075224 A NO20075224 A NO 20075224A NO 20075224 A NO20075224 A NO 20075224A NO 20075224 L NO20075224 L NO 20075224L
Authority
NO
Norway
Prior art keywords
optically active
cytosin
oxathiolane
hydroxymethyl
processes
Prior art date
Application number
NO20075224A
Other languages
English (en)
Other versions
NO338553B1 (no
Inventor
Dan Simion
Alex Cimpoia
Original Assignee
Shire Biochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Biochem Inc filed Critical Shire Biochem Inc
Publication of NO20075224L publication Critical patent/NO20075224L/no
Publication of NO338553B1 publication Critical patent/NO338553B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

Det blir skaffet til veie en fremgangsmåte for oppløsning av en forbindelse med formel III, i cis konfigurasjon: Det blir også skaffet til veie en fremgangsmåte for fremstilling av optisk aktive forbindelser med formel I eller II: der: Ri, R2,R3 er som definert her, idet metoden og fremgangsmåten involverer fremstilling, utvinning og omdanning av diastereomere salter.
NO20075224A 2005-03-14 2007-10-11 Prosess og fremgangsmåter for fremstilling av optisk aktiv CIS-2-hydroxymethyl-4-(cytosin-1'-YL)-1,3 oxathiolan eller farmasøytisk akseptable salter derav NO338553B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2005/000384 WO2006096954A1 (en) 2005-03-14 2005-03-14 Process and methods for the preparation of optically active cis-2-hydroxymethyl-4-(cytosin-1´-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof

Publications (2)

Publication Number Publication Date
NO20075224L true NO20075224L (no) 2007-10-11
NO338553B1 NO338553B1 (no) 2016-09-05

Family

ID=36991222

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075224A NO338553B1 (no) 2005-03-14 2007-10-11 Prosess og fremgangsmåter for fremstilling av optisk aktiv CIS-2-hydroxymethyl-4-(cytosin-1'-YL)-1,3 oxathiolan eller farmasøytisk akseptable salter derav

Country Status (15)

Country Link
EP (1) EP1866303B1 (no)
JP (1) JP5001254B2 (no)
KR (1) KR100993031B1 (no)
CN (1) CN101142211B (no)
AP (1) AP2261A (no)
AU (1) AU2005329355B8 (no)
BR (1) BRPI0520041A2 (no)
CA (1) CA2599825C (no)
ES (1) ES2446102T3 (no)
IL (1) IL185370A0 (no)
MX (1) MX2007011274A (no)
NI (1) NI200700235A (no)
NO (1) NO338553B1 (no)
NZ (1) NZ560972A (no)
WO (1) WO2006096954A1 (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110257396A1 (en) * 2006-10-30 2011-10-20 Lupin Limited Process for the manufacture of cis(-)-lamivudine
IN2015DN02599A (no) 2007-09-28 2015-09-18 Avexa Ltd
EP2358708B1 (en) * 2008-12-08 2013-06-12 Hetero Research Foundation Optical resolution of substituted 1.3-oxathiolane nucleosides
WO2011141805A2 (en) 2010-05-14 2011-11-17 Lupin Limited An improved process for the manufacture of lamivudine
JP2012136526A (ja) * 2012-02-09 2012-07-19 Shire Canada Inc 光学的に活性なｃｉｓ−２−ヒドロキシメチル−４−（シトシン−１’−イル）−１，３−オキサチオランまたはその薬学的に許容される塩の製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2095613C (en) * 1990-11-13 2001-01-02 Bernard Belleau Substituted 1, 3-oxathiolanes and substituted 1, 3-dithiolanes with antiviral properties
US5587480A (en) * 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
US6228860B1 (en) 1990-11-13 2001-05-08 Biochem Pharma Inc. Substituted 1,3-oxathiolanes with antiviral properties
NZ241625A (en) * 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
US6600044B2 (en) * 2001-06-18 2003-07-29 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers

Also Published As

Publication number Publication date
AU2005329355B2 (en) 2011-08-18
CN101142211B (zh) 2013-06-05
AP2261A (en) 2011-07-26
AU2005329355A1 (en) 2006-09-21
NZ560972A (en) 2009-07-31
KR20080008322A (ko) 2008-01-23
MX2007011274A (es) 2008-03-13
WO2006096954A1 (en) 2006-09-21
EP1866303A1 (en) 2007-12-19
ES2446102T3 (es) 2014-03-06
EP1866303B1 (en) 2013-11-27
KR100993031B1 (ko) 2010-11-08
CA2599825A1 (en) 2006-09-21
AP2007004147A0 (en) 2007-10-31
IL185370A0 (en) 2008-02-09
CA2599825C (en) 2012-06-19
EP1866303A4 (en) 2010-05-19
NI200700235A (es) 2012-05-23
AU2005329355B8 (en) 2012-02-23
NO338553B1 (no) 2016-09-05
JP2008533056A (ja) 2008-08-21
JP5001254B2 (ja) 2012-08-15
CN101142211A (zh) 2008-03-12
BRPI0520041A2 (pt) 2009-04-14

Similar Documents

Publication Publication Date Title
NO20054852L (no) GFAT inhibitorer
TN2009000024A1 (en) Prodrug of cinnamide compound
NO20072689L (no) Tetrasykliske indolderivater som antivirale midler
NO20062689L (no) Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer
NO20081476L (no) Substituerte benzimidazoler og fremgangsmater for fremstilling
NO20064077L (no) Kemokinreseptorantagonister
DE602005023015D1 (de) Indolderivate als viruzide
NO20091025L (no) Arylsulfonamider med analgesisk virkning
NO20075626L (no) Heteroarylbenzamid-derivater for anvendelse som GLK-aktivatorer i behandling av diabetes
TW200626598A (en) Pyrrazolo-pyrimidine derivatives
NO20060847L (no) Substituert 2-aminotetralin til behandling av depresjon
NO20053748L (no) Pyrrolopyridazinderivater.
NO20090166L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
WO2006113509A3 (en) Quinobenzoxazine analogs and methods of using thereof
WO2009018065A3 (en) Novel glucokinase activators and methods of using same
NO20054135L (no) Kipolinon/benzoksazin derivater og anvendelser derav
NO20076357L (no) Azabicykliske heterocykler som cannabinoid reseptor modulatorer
NO20075224L (no) Prosess og fremgangsmater for fremstilling av optisk aktiv CIS-2-hydroxymethyl-4-(cytosin-1'-YL)-1,3 oxathiolan eller farmasoytisk akseptable salter derav
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
NO20080394L (no) N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav
EP1861391A4 (en) SUBSTITUTED SULFOXIDE DERIVATIVES, SYNTHESIS METHODS THEREOF, AND APPLICATIONS OF SAID DERIVATIVES
BR0011902A (pt) Compostos derivados de ciclopentano substituìdo, respectivos processos de preparação e formas cristalinas
NO20063111L (no) Fremgangsmate for fremstilling av tiazolpyrimidiner
ATE466003T1 (de) Herstellung von 2-aminothiazol-5- carbonsäurederivaten
NO20084804L (no) Disazosyre-fargestoffer

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees